Ceftriaxone, either monotherapy or in dual therapy with azithromycin, is the mainstay of treatment of patients diagnosed with *Neisseria gonorrhoeae* infection in most settings ([@R1]). Therefore, the identification of any strains exhibiting resistance to ceftriaxone is of considerable public health concern. Until 2017, ceftriaxone-resistant strains of *N. gonorrhoeae* had been rare and typically sporadic, including in 2009, H041 in Japan ([@R2]); in 2010, F89 in France ([@R3]); in 2011, F89 in Spain ([@R4]); in 2013, A8806 in Australia ([@R5]); in 2014, GU140106 in Japan ([@R6]); and in 2015, FC428 and FC460 in Japan ([@R7]). However, there is now evidence of sustained international transmission of FC428, reported during 2017 in Canada ([@R8]) and Demark ([@R9]) (1 case each) and in Australia (2 cases) ([@R10]). Rapid and timely detection is pivotal to contain further spread of antimicrobial drug--resistant *N. gonorrhoeae*. Here, we describe a real-time PCR protocol to facilitate enhanced surveillance for the FC428 clone. The study was approved by the University of Queensland Human Research Ethics Committee.

The Study
=========

We designed a real-time PCR to target unique sequences on the *penA* gene of the FC428 *N. gonorrhoeae* clone ([@R10]). Modifications of *penA*, which encodes penicillin-binding protein 2 (PBP2), are a cause of cephalosporin resistance in *N. gonorrhoeae*. The FC428 clone harbors a mosaic *penA*-allele, designated as PenA-60.001 by results of *N. gonorrhoeae* sequence typing for antimicrobial drug resistance ([@R10]), and encodes alterations including A311V and T483S that have previously been associated with *N. gonorrhoeae* ceftriaxone resistance in H041 ([@R2]) and A8806 ([@R2],[@R5]) strains. For this study, we designed 2 primers and 2 allele-specific probes ([Table 1](#T1){ref-type="table"}) to facilitate specific detection of the *penA* gene of FC428. In brief, the forward and reverse primers were designed to flank the A311V alteration; probe 1 was designed for detection of the A311V alteration; and probe 2 was designed to detect the wild-type A311 sequence. We added probe 2 to act as a blocker probe to limit binding of probe 1 with the wild-type sequence.

###### Primer and probe sequences for PCR to detect *Neisseria gonorrhoeae* FC428 strain\*

  Designation      Oligonucleotide sequence, 5′ → 3′
  ---------------- ---------------------------------------
  Forward primer   CGCAACCGTGCCGTT
  Reverse primer   GGGTATTGAATGTGTCTGTTGGA
  Probe 1          Fam-TTCA+T+G+A+CA+G+AAC-Iowa Black FQ
  Probe 2          Hex-TCA+T+G+G+CA+GA-Iowa Black FQ

\*LNA bases are indicated by + preceding the base in the sequence.

We prepared the reaction mix by using the QuantiTect Probe PCR Master Mix Kit (QIAGEN, Doncaster, Victoria, Australia). The reaction consisted of 12.5 µL of the Master Mix, 10 pmol/L of forward and reverse primers ([Table 1](#T1){ref-type="table"}), 4.0 pmol/L of each probe, and 5.0 µL of specimen nucleic acid, resulting in a total volume of 25 µL. We thermocycled the reaction mix by using the Rotor-Gene 6000 instrument (QIAGEN) and held it at 95°C for 15 min, then cycled (45 cycles) at 95°C for 15 s and 60°C for 60 s. We analyzed data by using the Rotor-Gene allelic discrimination software (QIAGEN).

We initially assessed the analytical performance of the assay by testing cultured isolates of *N. gonorrhoeae* (n = 72) and commensal *Neisseria* and *Moraxella* species (n = 111) ([Table 2](#T2){ref-type="table"}). We prepared these isolates by using a previously described heat-denaturation method ([@R11]). The *N. gonorrhoeae* isolates included the 2 FC428 strains recently documented in Australia ([@R10]), H041 ([@R2]) and A8806 ([@R5]); the ceftriaxone-resistant strains; and other local clinical *N. gonorrhoeae* isolates (n = 68). Both FC428 isolates provided strong positive signals by using probe 1 with cycle threshold (C~t~) values \<20 cycles. The A8806 strain provided a late reaction at 37.8 cycles (probe 1), as did 2 commensal *Neisseria* strains: 1 *N. lactamica* isolate at 42.8 cycles for (probe 1), and 1 *N. meningitidis* isolate at 32.6 cycles (probe 2). The [Figure](#F1){ref-type="fig"}shows a sequence alignment of the partial *penA* sequences from these 3 isolates compared with the FC428 PenA-60.001 allele. The A8806 strain shows considerable sequence homology with PenA-60.001 (including 100% match with the A311V Probe 1 sequence), albeit for 2 mutations in the forward primer designed to limit detection of A8806. We do not consider this a limitation of the assay because there has only been 1 reported case of infection with the A8806 strain. Neither the *N. lactamica* or *N. meningitidis* isolates harbored the A311V alteration.

###### *Neisseria* spp. isolates and specimens tested in development of PCR to detect *Neisseria gonorrhoeae* FC428 strain\*

  Isolates/samples                                             PCR results for FC428 (C~t~)       
  ------------------------------------------------------------ ---------------------------------- ------------------------
  Probe 1                                                      Probe 2                            
  Gonococcal species, n = 144                                                                     
  *Neisseria gonorrhoeae*, n = 72                                                                 
  *N. gonorrhoeae* FC428, n = 2 ([@R9])†                       Positive (19.8 and 18.17 cycles)   Negative
  *N. gonorrhoeae* H041, n = 1 ([@R1])                         Negative                           Negative
  *N. gonorrhoeae* A8806, n = 1 ([@R4])                        Positive (37. 8 cycles)            Negative
  *N. gonorrhoeae*, n = 68‡                                    Negative                           Negative
  Nongonococcal species, n = 111                                                                  
  *N. cinerea*, n = 4                                          Negative                           Negative
  *N. elongata*, n = 1                                         Negative                           Negative
  *N. flavescens,* n = 1                                       Negative                           Negative
  *N. lactamica,* n = 15                                       Negative                           Negative
  *N. lactamica,* n = 1                                        Positive (42.8 cycles)             Negative
  *N. meningitidis,* n = 55                                    Negative                           Negative
  *N. meningitidis,* n = 1                                     Negative                           Positive (32.6 cycles)
  *N. mucosa,* n = 1                                           Negative                           Negative
  *N. polysacchareae*, n = 4                                   Negative                           Negative
  *N. sicca,* n = 4                                            Negative                           Negative
  *N. subflava,* n = 14                                        Negative                           Negative
  *N. weaveri*, n = 1                                          Negative                           Negative
  *Moraxella catarrhalis*, n = 7                               Negative                           Negative
  *M. osloensis*, n = 2                                        Negative                           Negative
  *N. gonorrhoeae* NAAT-positive clinical specimens, n = 358                                      
  Urogenital, n = 172                                          Negative                           Negative
  Anal swab, n = 81                                            Negative                           Negative
  Throat swab, n = 95                                          Negative                           Negative
  Other, n = 10                                                Negative                           Negative

\*Ct, cycle threshold; NAAT, nucleic acid amplification test. †Isolates A7846 and A7536. ‡Other local clinical isolates collected in New South Wales, Australia.
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To compare detection limits, we tested 10-fold dilutions of FC428 DNA by both the FC428 PCR and a previously described in-house *N. gonorrhoeae* PCR, directed at the gonococcal *porA* and *opa* sequences ([@R12]). The in-house *N. gonorrhoeae* PCR had the lowest detection limit at 0.3 genome copies/reaction, whereas the detection limit of the FC428 PCR was 3.0 genome copies/reaction, indicating the FC428 PCR was 1 log less sensitive than the diagnostic method.

We then applied the assay to a convenience panel of *N. gonorrhoeae*--positive clinical samples (n = 358) submitted to Pathology Queensland Laboratory (Brisbane, Queensland, Australia) during February--September 2017 ([Table 2](#T2){ref-type="table"}). In brief, these samples comprised remnant nucleic acids from samples that tested positive for *N. gonorrhoeae* by the Cobas 4800 CT/NG test and were confirmed positive by using the in-house *N. gonorrhoeae* PCR ([@R12]). All samples provided negative results by the FC428 PCR, suggesting that the FC428 strain was not present in Queensland during this period.

Conclusions
===========

Overall, our results suggest that the FC428 PCR is suitable for screening for the FC428 *N. gonorrhoeae* clone in clinical specimens for which culture is not available. The method could prove to be a strategic tool to enhance surveillance if FC428 continues to spread. We recommend that positive results be confirmed by, for example, DNA sequencing, particularly if the strain is detected in a pharyngeal sample in which other commensal *Neisseria* species are prevalent.
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